Jeffrey Nelson
Vermögen: 55 331 $ am 31.07.2026
Vermögen: 55 331 $ am 31.07.2026
Jeffrey Nelson is Chief Operating Officer at Milestone Pharmaceuticals, Inc. since 2020.
Formerly, Mr. Nelson was Vice President-Program Management at Oncotelic Therapeutics, Inc. from 2015 to 2017 and Head-Clinical Operations at Axsome Therapeutics, Inc. from 2014 to 2015.
Mr. Nelson completed an undergraduate degree at Brandeis University in 2003.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 02.02.2026 | 49’848 ( 0.04% ) | 55 331 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Geschäftsführer | 01.06.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2017 |
| AXSOME THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc. BiotechnologyHealth Technology Engages in developing novel small-molecule therapeutics to treat cancer and eye diseases | Health Technology |
Milestone Pharmaceuticals, Inc.
Milestone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cardiovascular medicines | Health Technology |
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. BiotechnologyHealth Technology Develops and manufactures novel therapies for the management of central nervous system | Health Technology |
Brandeis University
Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen